Leukemia Research
Volume 32, Issue 2 , Pages 255-261 , February 2008

Imatinib mesylate therapy in chronic myeloid leukemia patients in stable complete cytogenic response after interferon-alpha results in a very high complete molecular response rate

  • Giuliana Alimena

      Affiliations

    • Department of Cellular Biotechnologies and Hematology, University “La Sapienza”, Rome, Italy
    • Corresponding Author InformationCorresponding author at: Department of Cellular Biotechnologies and Hematology, Via Benevento 6, 00161 Rome, Italy.
    • ,
  • Massimo Breccia

      Affiliations

    • Department of Cellular Biotechnologies and Hematology, University “La Sapienza”, Rome, Italy
    • ,
  • Luigia Luciano

      Affiliations

    • CEINGE Biotecnologie Avanzate and Department of Biochemistry and Medical Biotechnology, University of Naples Federico II, Italy
    • ,
  • Fabrizio Quarantelli

      Affiliations

    • CEINGE Biotecnologie Avanzate and Department of Biochemistry and Medical Biotechnology, University of Naples Federico II, Italy
    • ,
  • Daniela Diverio

      Affiliations

    • Department of Cellular Biotechnologies and Hematology, University “La Sapienza”, Rome, Italy
    • ,
  • Barbara Izzo

      Affiliations

    • CEINGE Biotecnologie Avanzate and Department of Biochemistry and Medical Biotechnology, University of Naples Federico II, Italy
    • ,
  • Biagio De Angelis

      Affiliations

    • CEINGE Biotecnologie Avanzate and Department of Biochemistry and Medical Biotechnology, University of Naples Federico II, Italy
    • ,
  • Marco Mancini

      Affiliations

    • Department of Cellular Biotechnologies and Hematology, University “La Sapienza”, Rome, Italy
    • ,
  • Roberto Latagliata

      Affiliations

    • Department of Cellular Biotechnologies and Hematology, University “La Sapienza”, Rome, Italy
    • ,
  • Ida Carmosino

      Affiliations

    • Department of Cellular Biotechnologies and Hematology, University “La Sapienza”, Rome, Italy
    • ,
  • Mauro Nanni

      Affiliations

    • Department of Cellular Biotechnologies and Hematology, University “La Sapienza”, Rome, Italy
    • ,
  • Marco Picardi

      Affiliations

    • CEINGE Biotecnologie Avanzate and Department of Biochemistry and Medical Biotechnology, University of Naples Federico II, Italy
    • ,
  • Bruno Rotoli

      Affiliations

    • CEINGE Biotecnologie Avanzate and Department of Biochemistry and Medical Biotechnology, University of Naples Federico II, Italy
    • ,
  • Franco Mandelli

      Affiliations

    • Department of Cellular Biotechnologies and Hematology, University “La Sapienza”, Rome, Italy
    • ,
  • Fabrizio Pane

      Affiliations

    • CEINGE Biotecnologie Avanzate and Department of Biochemistry and Medical Biotechnology, University of Naples Federico II, Italy

Received 8 April 2007 ,Revised 4 June 2007 ,Accepted 6 June 2007.

References 

  1. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science. 1990;247:824–830
  2. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon alfa-2a compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med. 1994;330:820–825
  3. Hehlmann R, Berger U, Pfirrmann M, et al. Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and hydroxyurea. Leukemia. 2003;17:1529–1537
  4. Hochhaus A, Reiter A, Saussele S, et al. Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. Blood. 2000;95:62–66
  5. Bonifazi F, de Vivo A, Rosti G, et al. Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood. 2001;98:3074–3081
  6. Mahon FX, Delbrel X, Cony-Makhoul P, et al. Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alfa. J Clin Oncol. 2002;20:214–220
  7. Kantarjian HM, O’Brien S, Cortes J, et al. Complete cytogenetic and molecular responses to IFN-alpha based therapy for chronic myeloid leukemia are associated with excellent long-term prognosis. Cancer. 2003;97:1033–1041
  8. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031–1037
  9. Kantarjian HM, Cortes JE, O’Brien S, et al. Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive, chronic-phase chronic myeloid leukemia after failure of interferon-{alpha}. Blood. 2004;104:1979–1988
  10. O’Brien SG, Guilhot F, Larson RA, et al. IRIS Investigators. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994–1004
  11. Branford S, Rudzki Z, Harper A, et al. Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Leukemia. 2003;17:2401–2409
  12. Druker BJ, Guilhot FG, O’Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408–2417
  13. Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2003;349:1423–1432
  14. Muller MC, Gattermann N, Lahaye T, et al. Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C. Leukemia. 2003;17:2392–2400
  15. Paschka P, Muller MC, Merx K, et al. Molecular monitoring of response to imatinib (Glivec) in CML patients pre-treated with interferon alpha, low levels of residual disease are associated with continuous remission. Leukemia. 2003;17:1687–1694
  16. Hochhaus A, La Rosee P. Imatinib therapy in chronic myelogenous leukaemia: strategies to avoid and overcome resistance. Leukemia. 2004;18:1321–1331
  17. Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leucemia:recommendations from an export panel on behalf of the European LeukemiaNet. Blood. 2006;108:1809–1820
  18. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002;346:645–652
  19. van Dongen JJ, Macintyre EA, Gabert JA, et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia. 1999;13:1901–1928
  20. Gabert J, Beillard E, van der Velden VH, et al. Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukaemia—a Europe Against Cancer program. Leukemia. 2003;17:2318–2357
  21. Chronic myeloid leukaemia Trialists’ Collaborative Group. Interferon alpha versus chemotherapy for chronic myeloid leukaemia: a meta-analysis of seven randomized trials. J Natl Cancer Inst. 1997;89:1616–1620
  22. Guilhot F, Chastang C, Michallet M, et al. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. N Engl J Med. 1997;337:223–229
  23. Kantarjian H, Talpaz M, O’Brien S, et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood. 2004;103:2873–2878
  24. Mauro MJ, Deininger MW. Chronic myeloid leukemia in 2006: a perspective. Haematologica. 2006;91:152
  25. Branford S, Rudzki Z, Parkinson I, et al. Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Blood. 2004;104:2926–2932
  26. Baccarani M, Martinelli G, Rosti G, et al. GIMEMA Working Party on Chronic Myeloid Leukemia. Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia. Blood. 2004;104:4245–4251
  27. Bhatia R, Holtz M, Niu N, et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood. 2003;101:4701–4707
  28. Rousselot P, Huguet F, Rea D, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood. 2007;109:58–60
  29. Hehlmann R, Berger U, Hochhaus A. Chronic myeloid leukemia: a model for oncology. Ann Hematol. 2005;84:487–497

PII: S0145-2126(07)00250-0

doi: 10.1016/j.leukres.2007.06.008

Leukemia Research
Volume 32, Issue 2 , Pages 255-261 , February 2008

Article Tools

* Image Usage & Resolution